London, 22 July 2015: Technavio, the independent tech-focused global research firm, has published a report on the global glioblastoma multiforme therapeutics market 2015-2019, which is expected to post a CAGR of 11.94% during the forecast period of 2014-2019.
The market is expected to witness the entry of novel therapeutics in the form of drugs and vaccines for treating patients. Also, treatments such as immunotherapies DCVax-L by Northwest Biotherapeutics and rindopepimut by Celldex Therapeutics are the promising vaccine candidates which will enter the market during the forecast period.
“The expected entry of novel late-stage pipeline candidates to treat glioblastoma multiforme is expected to propel the growth of the market positively,” says Faisal Ghaus, Vice President of Technavio.
“The immunotherapeutic agents which are currently under Phase III trials are expected to hit the market during the forecast period, and generate a substantial amount of revenue. These pipeline candidates are expected to cater to a large extend to the substantial unmet medical need present in the market.”
Key Market Drivers
- Unmet Medical Need
- Rising Incidence of Glioblastoma Multiforme
- Presence of Late-stage Pipeline Candidates
- Provision for Orphan Drugs
- Designated Under ICD-10 Code
Key Market Trends
- Expected Entry of Novel Agents
- Increasing Public Awareness
- Strategic Alliances
Key Market Vendors
- Arbor Pharmaceuticals LLC
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Ltd.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
